Surgical treatments for men with benign prostatic enlargement: cost effectiveness study
Authors:
- Ghulam NabiGNGhulam Nabi
- Robert PickardRPRobert Pickard
- for the BPE Study GroupFGfor the BPE Study Group
Open Access
Abstract
Objective To determine which surgical treatment for lower urinary tract symptoms suggestive of benign prostate enlargement is cost effective. Design Care pathways describing credible treatment strategies were decided by consensus. Cost-utility analysis used Markov modelling and Monte Carlo simulation. Data sources Clinical effectiveness data came from a systematic review and an individual level dataset. Utility values came from previous economic evaluations. Costs were calculated from National Health Service (NHS) and commercial sources. Methods The Markov model included parameters with associated measures of uncertainty describing health states between which individuals might move at three monthly intervals over 10 years. Successive annual cohorts of 25 000 men were entered into the model and the probability that treatment strategies were cost effective was assessed with Monte Carlo simulation with 10 000 iterations. Results A treatment strategy of initial diathermy vaporisation of the prostate followed by endoscopic holmium laser enucleation of the prostate in case of failure to benefit or subsequent relapse had an 85% probability of being cost effective at a willingness to pay value of £20 000 (€21 595, $28 686)/quality adjusted life year (QALY) gained. Other strategies with diathermy vaporisation as the initial treatment were generally cheaper and more effective than the current standard of transurethral resection repeated once if necessary. The use of potassium titanyl phosphate laser vaporisation incurred higher costs and was less effective than transurethral resection, and strategies involving initial minimally invasive treatment with microwave thermotherapy were not cost effective. Findings were unchanged by wide ranging sensitivity analyses. Conclusion The outcome of this economic model should be interpreted cautiously because of the limitations of the data used. The finding that initial vaporisation followed by holmium laser enucleation for failure or relapse might be advantageous both to men with lower urinary tract symptoms and to healthcare providers requires confirmation in a good quality prospective clinical trial before any change in current practice. Potassium titanyl phosphate laser vaporisation was unlikely to be cost effective in our model, which argues against its unrestricted use until further evidence of effectiveness and cost reduction is obtained.Keywords
This publication has 23 references indexed in Scilit:
- Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trialsBMJ, 2008
- Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trialsBMJ, 2008
- Photoselective Potassium Titanyl Phosphate (KTP) Laser Vaporization Versus Transurethral Resection of the Prostate for Prostates Larger Than 70 mL: A Short-Term Prospective Randomized TrialUrology, 2008
- A Clinical Outcomes and Cost Analysis Comparing Photoselective Vaporization of the Prostate to Alternative Minimally Invasive Therapies and Transurethral Prostate Resection for the Treatment of Benign Prostatic HyperplasiaJournal of Urology, 2006
- Reoperation, Myocardial Infarction and Mortality after Transurethral and Open Prostatectomy: A Nation-Wide, Long-Term Analysis of 23,123 CasesEuropean Urology, 2005
- A Systematic Review of Holmium Laser Prostatectomy for Benign Prostatic HyperplasiaJournal of Urology, 2004
- Expected Value of Sample Information Calculations in Medical Decision ModelingMedical Decision Making, 2004
- The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik studyBJU International, 2003
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Journal of Urology, 1995
- A Comparison of Transurethral Surgery with Watchful Waiting for Moderate Symptoms of Benign Prostatic HyperplasiaNew England Journal of Medicine, 1995